Twist Bioscience (NASDAQ:TWST) Price Target Raised to $48.00 at Robert W. Baird

Twist Bioscience (NASDAQ:TWST) had its price objective hoisted by Robert W. Baird from $46.00 to $48.00 in a research note released on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other analysts have also recently issued research reports about the stock. Evercore ISI boosted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.78.

Twist Bioscience Stock Down 0.3 %

Twist Bioscience stock opened at $41.32 on Tuesday. The company has a 50 day moving average of $43.99 and a 200-day moving average of $46.18. Twist Bioscience has a twelve month low of $23.00 and a twelve month high of $60.90. The stock has a market capitalization of $2.42 billion, a PE ratio of -10.82 and a beta of 1.78.

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the sale, the insider now owns 91,163 shares in the company, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Chess sold 3,600 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00. Following the transaction, the director now owns 21,641 shares of the company’s stock, valued at $1,022,753.66. This represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 over the last 90 days. Insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently bought and sold shares of TWST. American International Group Inc. grew its stake in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after buying an additional 213 shares during the period. Caprock Group LLC lifted its holdings in shares of Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after acquiring an additional 220 shares during the last quarter. Signaturefd LLC boosted its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. Arizona State Retirement System grew its stake in shares of Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after buying an additional 308 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after acquiring an additional 312 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.